DAVID KROIN

CIK 1397513 · last filed 2026-08-10

DAVID KROIN is a corporate insider who has filed 43 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for ATTO, was dated Aug 10, 2026. Across all open-market trades the lifetime net is −$37.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $126.7M across reported positions. 41 SEC filings were submitted jointly with GREAT POINT PARTNERS LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$126.71M

Companies

5

Total Filings

43

Lifetime Open-Market Net

-$37.75M

Filer Profile

Reported Address
C/O DEEP TRACK CAPITAL, LP
200 GREENWICH AVENUE, 3RD FLOOR
GREENWICH, CT 06830
Related Filers
GREAT POINT PARTNERS LLC — 41 joint filings, latest 2018-09-14
JEFFREY R JAY — 18 joint filings, latest 2018-09-14
Deep Track Biotechnology Master Fund, Ltd. — 11 joint filings, latest 2026-08-10
Deep Track Capital, LP — 11 joint filings, latest 2026-08-10
GREAT POINT PARTNERS I LP — 4 joint filings, latest 2015-07-16
Great Point Partners I GP, LLC — 4 joint filings, latest 2015-07-16
Attovia Therapeutics, Inc. — 2 joint filings, latest 2026-08-10
Deep Track Special Opportunities Fund, LP — 1 joint filings, latest 2026-02-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ATTO 10%+ Owner 1,957,138 $17.84 $34.92M $0 1 2026-08-10
Foamix Pharmaceuticals Ltd. (FOMX) Delisted 4,781,708 — — $0 1 2018-09-14
INFU 10%+ Owner 1,955,000 $12.75 $24.93M -$30.46M 1 2011-02-10
ALBIREO PHARMA, INC. (BIOD) Delisted Director 94,059 — — -$7.22M 39 2010-03-03
MEMY 10%+ Owner 4,059,852 $16.47 $66.87M -$74.7K 1 2008-12-11

Recent Filings

43 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-10 ATTO Conv (C) +5,871,414 $0 EDGAR
2018-09-14 Foamix Pharmaceuticals Ltd. (FOMX) Delisted — — $0 EDGAR
2011-02-10 INFU Sell (S) −13,500,000 -$30.46M EDGAR
2010-03-03 ALBIREO PHARMA, INC. (BIOD) Delisted Grant (A) — $0 EDGAR
2010-01-15 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −166,490 -$844.6K EDGAR
2010-01-05 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −157,780 -$798.4K EDGAR
2009-10-23 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −2,600 -$13.0K EDGAR
2009-10-21 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −6,534 -$32.8K EDGAR
2009-10-09 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −52,026 -$269.6K EDGAR
2009-09-24 ALBIREO PHARMA, INC. (BIOD) Delisted Sell (S) −19,590 -$101.9K EDGAR
Showing 1–10 of 43
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.